How do you reach "8% - 10% from the growth in clinical trials that require measurement of cognition as an endpoint"? Why not 15%-20%?
And when you say "I think the more important question is how many later stage trials", how can we get a sense of that number? I mean, how many of such trials are currently being ran for AD?
And regarding my last question, I was actually thinking about Aducanumab not being approved. Brad has said that he doesn't feel that it will impact Cogstate much, but why has it impacted Cogstate a couple of years ago and not now? Wouldn't the industry go back to the drawing board?
Cheers
CGS Price at posting:
87.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)